None listed
Conditions
Brief summary
Strontium Ranelate is approved for treatment of osteoporosis. Its mode of action is thought to be a combination of anti resorptive and anabolic on bone. The bone forming ability has been documented in animal studies as well as in the increase in level of P1NP (A bone formation marker). There are anecdotal reports that it enhances fracture healing in humans but very little prospective data is present. The purpose of this study is to study the efficacy of strontium ranelate in the dose of 2gm daily on the healing of surgically fixed diaphyseal tibial fractures and compare it to placebo.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
All adult patients between 18 and 60 years of age presenting with closed diaphysial tibial fractures, amenable to fixation with a Dynamic Compression Plate / Locking Compression Plate
Exclusion criteria
All open fractures Patients under 18 yrs or over 60 yrs Metaphyseal /periarticular fractures Patients with previous procedures in that limb Fractures requiring bone grafting Pregnant patients Patients with renal impairment